Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells

Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells

Clinical resistance to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) remains a significant challenge. Recent studies have indicated that the number of myeloid-derived suppressor cells (MDSCs) increases following gefitinib treatment, correlating with a poor patient response in...

Full description

Bibliographic Details
Main Authors: Jinjin Shao, Zhichao Ye, Zeren Shen, Nienwei Liu, Lijiang Zhang, Masashi Tachibana, Zhiqi Xie
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Chidamide
Gefitinib
MDSC
NSCLC
CCL2/CCR2
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332224001872

Internet

http://www.sciencedirect.com/science/article/pii/S0753332224001872

Similar Items